Zobrazeno 1 - 3
of 3
pro vyhledávání: '"AMLN, amylin liver NASH"'
Autor:
James L. Trevaskis, Anthony Celeste, Michelle L. Boland, Sarah Will, Silvia Guionaud, Stephanie Oldham, Peter Ravn, Hani A. Jouihan
Publikováno v:
Molecular Metabolism, Vol 6, Iss 11, Pp 1360-1370 (2017)
Molecular Metabolism
Molecular Metabolism
Objective Nonalcoholic steatohepatitis (NASH) is an unmet need associated with metabolic syndrome. There are no approved therapies for NASH; however, glucagon-like peptide-1 receptor (GLP-1R) and farnesoid-X receptor (FXR) agonists are promising drug
Publikováno v:
JHEP Reports
JHEP Reports, Vol 3, Iss 1, Pp 100193-(2021)
JHEP Reports, Vol 3, Iss 1, Pp 100193-(2021)
Background & Aims Thrombospondin 1 (TSP1) is a multifunctional matricellular protein. We previously showed that TSP1 has an important role in obesity-associated metabolic complications, including inflammation, insulin resistance, cardiovascular, and
Autor:
Gwag T; Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY 40536, USA., Reddy Mooli RG; Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY 40536, USA., Li D; Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY 40536, USA., Lee S; Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY 40536, USA., Lee EY; Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY 40536, USA., Wang S; Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY 40536, USA.
Publikováno v:
JHEP reports : innovation in hepatology [JHEP Rep] 2020 Oct 09; Vol. 3 (1), pp. 100193. Date of Electronic Publication: 2020 Oct 09 (Print Publication: 2021).